Revenue and Profit Performance - Revenue for the third quarter was RMB 2.09 billion, a decrease of 4.06% compared to the same period last year[2] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 179.89 million, a decrease of 44.67% year-on-year[2] - Cumulative revenue from the beginning of the year to the end of the reporting period was RMB 6.46 billion, a decrease of 1.66% compared to the same period last year[2] - Cumulative net profit attributable to shareholders of the listed company from the beginning of the year to the end of the reporting period was RMB 325.12 million, a decrease of 18.41% year-on-year[2] - Total revenue for the first three quarters of 2024 was 6,462,559,794.57 RMB, a slight decrease from 6,571,392,090.82 RMB in the same period of 2023[17] - Net profit for the first three quarters of 2024 was 828,144,304.95 RMB, down from 1,000,105,317.73 RMB in the same period of 2023[18] - Revenue for the first three quarters of 2024 reached 4,324,188,522.33 RMB, up from 4,092,108,241.36 RMB in the same period last year[25] - Net profit for the first three quarters of 2024 was 871,685,138.46 RMB, down from 1,041,089,199.71 RMB in the same period last year[26] Profitability Factors - The decrease in net profit was mainly due to higher fair value losses on financial assets and lower gross margins from product price reductions[4] - Basic earnings per share for the third quarter were RMB 0.12, a decrease of 45.45% year-on-year[3] - Net profit attributable to shareholders of the parent company was 842,201,236.32 RMB, down from 1,032,219,095.72 RMB in the same period of 2023[18] - Basic earnings per share for the first three quarters of 2024 were 0.56 RMB, down from 0.69 RMB in the same period of 2023[19] Asset and Equity Changes - Total assets at the end of the reporting period were RMB 16.83 billion, an increase of 0.72% compared to the end of the previous year[3] - Shareholders' equity attributable to the listed company at the end of the reporting period was RMB 12.71 billion, an increase of 2.74% compared to the end of the previous year[3] - Tianshi Pharmaceutical Group's total current assets as of September 30, 2024, amounted to 9,071,544,282.27 RMB, compared to 8,732,680,895.93 RMB at the end of 2023[14] - Total assets increased to 16,834,745,203.85 RMB, up from 16,714,285,093.86 RMB in the previous period[15] - Total equity increased to 13,017,525,146.32 RMB from 12,690,009,062.97 RMB[16] - Total assets increased to 15,464,733,902.98 RMB, up from 15,410,450,008.24 RMB in the previous period[23] - Total equity attributable to shareholders rose to 11,945,130,957.33 RMB, up from 11,583,165,376.29 RMB previously[24] Financial Position and Liabilities - The company's monetary funds decreased to 3,635,664,278.51 RMB as of September 30, 2024, from 4,450,600,676.46 RMB at the end of 2023[13] - Tianshi Pharmaceutical Group's accounts receivable increased to 1,040,697,294.55 RMB as of September 30, 2024, from 688,003,223.63 RMB at the end of 2023[14] - The company's inventory decreased slightly to 1,708,285,219.12 RMB as of September 30, 2024, from 1,747,685,395.27 RMB at the end of 2023[14] - Tianshi Pharmaceutical Group's long-term equity investments decreased to 1,368,351,638.68 RMB as of September 30, 2024, from 1,415,412,097.78 RMB at the end of 2023[14] - The company's fixed assets decreased to 3,228,253,408.17 RMB as of September 30, 2024, from 3,388,718,651.12 RMB at the end of 2023[14] - Tianshi Pharmaceutical Group's development expenditure increased to 1,544,830,366.16 RMB as of September 30, 2024, from 1,452,896,953.08 RMB at the end of 2023[14] - The company's total non-current assets as of September 30, 2024, included 481,957,189.38 RMB in other non-current financial assets, down from 638,217,114.53 RMB at the end of 2023[14] - Tianshi Pharmaceutical Group's prepayments increased to 95,274,519.23 RMB as of September 30, 2024, from 65,572,406.23 RMB at the end of 2023[14] - The company's other receivables increased significantly to 86,552,069.72 RMB as of September 30, 2024, from 11,490,057.43 RMB at the end of 2023[14] - Total liabilities decreased to 3,817,220,057.53 RMB from 4,024,276,030.89 RMB in the previous period[16] - Short-term borrowings increased to 993,287,736.04 RMB from 723,051,144.30 RMB[15] - Short-term borrowings increased significantly to 896,570,694.44 RMB, up from 497,476,388.89 RMB previously[23] - Total liabilities decreased to 3,519,602,945.65 RMB, down from 3,827,284,631.95 RMB previously[23] Cash Flow and Investments - Cash received from sales of goods and services in the first three quarters of 2024 was 7,060,063,757.08 RMB, a decrease from 7,318,700,255.57 RMB in the same period of 2023[20] - Net cash flow from operating activities for the first three quarters of 2024 was 1,189,929,757.94 RMB, an increase from 1,089,487,406.49 RMB in the same period of 2023[21] - Cash received from investments in the first three quarters of 2024 was 4,983,417,806.61 RMB, a significant increase from 1,615,886,708.19 RMB in the same period of 2023[21] - Net cash flow from investing activities for the first three quarters of 2024 was -1,499,100,283.76 RMB, a decrease from -298,549,592.91 RMB in the same period of 2023[21] - Net cash flow from financing activities for the first three quarters of 2024 was -866,677,828.49 RMB, a decrease from -158,026,719.99 RMB in the same period of 2023[21] - The company's monetary funds as of September 30, 2024, were 2,235,324,918.20 RMB, a decrease from 3,221,847,242.03 RMB at the end of 2023[22] - The company's total current assets as of September 30, 2024, were 6,147,756,808.30 RMB, slightly increased from 6,128,717,018.14 RMB at the end of 2023[22] - Long-term equity investments as of September 30, 2024, were 6,589,887,702.87 RMB, a slight decrease from 6,629,227,183.33 RMB at the end of 2023[22] - Development expenditure rose to 909,513,693.87 RMB, compared to 828,481,492.63 RMB previously[23] - Cash flow from operating activities for the first three quarters of 2024 was 4,433,623,509.83 RMB, up from 4,365,765,773.15 RMB in the same period last year[27] - Total cash outflow from operating activities was 3,815,438,910.24 RMB, a slight increase from 3,803,717,675.71 RMB in the previous period[28] - Net cash flow from operating activities increased to 618,184,599.59 RMB, up from 562,048,097.44 RMB[28] - Cash inflow from investment activities surged to 5,453,758,056.45 RMB, more than double the previous 2,321,604,557.77 RMB[28] - Cash outflow for investments rose significantly to 6,515,144,853.19 RMB, compared to 2,821,158,230.68 RMB[28] - Net cash flow from investment activities was negative at -1,415,572,973.32 RMB, a larger outflow than the previous -746,101,885.43 RMB[28] - Cash inflow from financing activities decreased to 2,370,688,611.12 RMB, down from 2,759,510,000.00 RMB[28] - Net cash flow from financing activities turned negative at -320,184,257.48 RMB, compared to a positive 1,098,242,648.02 RMB in the previous period[28] - The net increase in cash and cash equivalents was negative at -1,117,572,631.21 RMB, a significant reversal from the previous positive 914,188,860.03 RMB[28] - Ending cash and cash equivalents balance dropped sharply to 777,778,960.59 RMB, down from 3,314,468,818.09 RMB[28] R&D and Sales Expenses - R&D expenses increased to 564,770,536.84 RMB, up from 558,324,364.38 RMB in the previous year[18] - Sales expenses decreased slightly to 2,209,020,849.25 RMB from 2,228,496,399.34 RMB in the previous year[18] - R&D expenses increased to 358,427,153.35 RMB, up from 319,711,789.99 RMB in the same period last year[25] Comprehensive Income and Other Financial Metrics - Comprehensive income for the first three quarters of 2024 reached 810,680,787.13 RMB, a decrease from 908,583,220.60 RMB in the same period of 2023[19] - Other comprehensive income showed a loss of 16,716,055.77 RMB, compared to a loss of 125,431,237.62 RMB in the same period last year[26] - Financial expenses showed a net income of 11,737,585.61 RMB, compared to a net income of 1,968,883.70 RMB in the previous year[18] Business Operations and Acquisitions - Pharmaceutical industrial revenue increased by 2.18%, while pharmaceutical commercial revenue decreased by 25.36%[4] - The company completed the acquisition of Tasly Healthcare Deutschland GmbH in October 2023, leading to adjustments in comparative financial data[4]

天士力医药集团股份有限公司 2024 年第三次独立董事专门会议决议 独立董事签名：张斌、王爱俭、韩秀桃 2024 年 10 月 25 日 1 一、审议通过《关于新增 2024 年度日常关联交易预计的议案》 经审查，我们认为：本次新增日常关联交易属于公司正常生产经营活动，关 联交易以市场价格或以成本加合理利润为依据，交易定价客观、公允，体现了公 平合理的市场化原则，不会对公司独立性产生影响，符合公司和全体股东的利益， 不存在损害公司及中小股东利益的情形，一致同意将该议案提交公司董事会审议。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 天士力医药集团股份限公司（以下简称"公司"）2024 年第三次独立董事专 门会议于 2024 年 10 月 25 日以通讯方式召开。本次会议由全体独立董事共同推 举张斌先生召集并主持。本次会议应到独立董事 3 人，实到独立董事 3 人。本次 会议的召开符合《上市公司独立董事管理办法》、《公司章程》、《独立董事工作制 度》等有关规定，经与会独立董事审议形成决议如下： ...

证券代码：600535 证券简称：天士力 编号：临 2024-044 号 天士力医药集团股份有限公司 经监事会对董事会编制的《2024 年第三季度报告》全文及摘要审慎审核，监 事会一致认为： （1）公司《2024 年第三季度报告》编制和审议程序符合法律、法规、《公司 章程》和公司内部管理制度的各项规定； （2）公司《2024 年第三季度报告》的内容和格式符合中国证监会和上海证 券交易所的各项规定，所包含的信息能从各个方面真实地反映出公司 2024 年第三 季度的经营管理和财务状况； （3）在提出本意见前，监事会未发现参与《2024 年第三季度报告》编制和审 议的人员有违反保密规定的行为。 内容详见公司在上海证券交易所网站（www.sse.com.cn）发布的《2024 年第 三季度报告》。 第九届监事会第 3 次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）第九届监事会第 3 次会议 通知和会议材料于 2024 年 10 月 15 日向全体监事及公司高级管理人 ...

证券代码：600535 证券简称：天士力 编号：临 2024-047 号 天士力医药集团股份有限公司 关于召开 2024 年第三次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024 年第三次临时股东大会 召开的日期时间：2024 年 11 月 11 日 15 点 30 分 召开地点：天津市北辰科技园区天士力现代中药城天士力医药集团股份有限 公司会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 11 月 11 日 至 2024 年 11 月 11 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"或"本公司"）第九届董事 会第 4 次会议通知和会议材料于 2024 年 10 月 15 日向全体董事、监事及公司高级 管理人员以直接送达、邮寄等方式发出，会议于 2024 年 10 月 25 日以通讯方式召 开。会议应到董事 9 人，实到 9 人，公司监事、高级管理人员等相关人员列席会 议。会议符合《公司法》和《公司章程》的有关规定，会议合法、有效。会议由 公司董事长闫凯境先生主持，经与会人员逐项审议，通过了以下议案： 1、《2024 年第三季度报告》 证券代码：600535 证券简称：天士力 编号：临 2024-043 号 天士力医药集团股份有限公司 第九届董事会第 4 次会议决议公告 3、关于新增 2024 年度日常关联交易预计的议案 本议案事先已经公司 2024 年第三次独立董事专门会议审议通过。该关联交易 议案关联董事闫凯境、蒋晓萌、李克新均回避了表决，其余六名董事表决全部通 过。内容详见公司在上海证券交易所网站（www ...

证券代码：600535 证券简称：天士力 编号：临 2024-042 号 天士力医药集团股份有限公司 2024 年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.26 元。 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/10/9 | － | 2024/10/10 | 2024/10/10 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司于 2024 年 9 月 9 日召开的 2024 年第二次临时股东大会审议通过。 二、分配方案 1. 发放年度：2024 年半年度 2. 分派对象： 3. 分配方案： 本次利润分配以方案实施前的公司总股本1,493,950,005股为基数，每股派发现金红利0.26 元（含税），共计派发现金红利 388,427,001.30 元。 三、相关日期 ...

证券代码：600535 证券简称：天士力 编号：临 2024-041 号 天士力医药集团股份有限公司 2024 年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2024 年 9 月 9 日 (二) 股东大会召开的地点：天津市北辰科技园区天士力现代中药城天士力医药 集团股份有限公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 697 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 714,457,076 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的 | 47.8233 | | 比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议采取现场投票与网络投票相结合的方式召开及表决。会议由公司董 事会召集，根据《公司章程》有关规定，经公 ...

证券代码：600535 证券简称：天士力 编号：临 2024-040 号 天士力医药集团股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，天士力医药集团股份有限公司（以下简称"公司"）之全资子公司江 苏天士力帝益药业有限公司（以下简称"江苏帝益"）收到国家药品监督管理局 核准签发的关于盐酸丙卡特罗口服溶液（以下简称"该药品"）的《药品注册证 书》，现将相关情况公告如下： 一、药品的基本情况 药品名称：盐酸丙卡特罗口服溶液 剂型：口服溶液剂 规格：60ml:0.3mg 注册分类：化学药品 3 类 证书编号：2024S02024 药品批准文号：国药准字 H20244723 上市许可持有人：江苏天士力帝益药业有限公司 药品生产企业：南京海纳制药有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的相关信息 1 治指南（2016 年版）》、《支气管哮喘防治指南（2020 年版）》等指南。该药 ...

2024 年第二次临时股东大会会议资料 天士力医药集团股份有限公司 2024 年第二次临时股东大会会议资料 现场会议召开时间：2024 年 9 月 9 日 15 点 30 分 网络投票系统及投票时间： 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 9 月 9 日 至 2024 年 9 月 9 日 2024 年 9 月 9 日 2024 年第二次临时股东大会会议资料 天士力医药集团股份有限公司 2024 年第二次临时股东大会议程 一、会议时间： 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会 召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的 投票时间为股东大会召开当日的 9:15-15:00。 二、会议地点：天津市北辰科技园区天士力现代中药城天士力医药集团股份有限公司会 议室 三、会议议程： （一）宣布会议正式开始 （二）宣布大会出席情况和事项的表决方法 （三）推举表决票清点人、监票人、结果宣布人 （四）宣读议案并请股东针对议案发表意见 | 非累积投票议案 | | | --- | - ...